Jennifer R. Rose-Nussbaumer

Dr. Jennifer R. Rose-Nussbaumer


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in Ophthalmology
Verified
Journal Article
Closed access
AAAriana Austin
Ariana Austin
TLTom Lietman
Tom Lietman
JRJennifer R. Rose-Nussbaumer
Jennifer R. Rose-Nussbaumer

1 December 2016 in JAMA Ophthalmology
Verified
Journal Article
Open access
PDF file
NPN. Venkatesh Prajna
N. Venkatesh Prajna
TKTiruvengada Krishnan
Tiruvengada Krishnan
RRRevathi Rajaraman
Revathi Rajaraman
SPSushila Patel
Sushila Patel
MSMuthiah Srinivasan
Muthiah Srinivasan
FGfor the Mycotic Ulcer Treatment Trial II Group
for the Mycotic Ulcer Treatment Trial II Group
Quiz Ref ID Fungal corneal ulcers present a therapeutic challenge to clinicians because of their poor outcomes and the sparse evidence to guide treatment.1-7 One study6 estimated that up to 1% of a population in South India would develop a central corneal ulcer and that up to 50% of these ulcers would be fungal. Although fungal ulcers are less common in the United States, they can occur after trauma, with contact lens wear, or after refractive surgery.8,9 An outbreak of Fusarium keratitis among contact lens wearers was related to the ReNu MoistureLoc contact lens solution (Bausch & Lomb), which was subsequently removed from the market.10

1 January 2019 in Ophthalmology
Verified
Journal Article
Closed access
WCWinston Chamberlain
Winston Chamberlain
CLCharles C. Lin
Charles C. Lin
AAAriana Austin
Ariana Austin
NSNicholas Schubach
Nicholas Schubach
JCJameson Clover
Jameson Clover
JRJennifer R. Rose-Nussbaumer
Jennifer R. Rose-Nussbaumer

17 October 2017 in Cornea
Verified
Journal Article
Closed access
MPMichelle Y. Peng
Michelle Y. Peng
VCVicky Mt Cevallos
Vicky Mt Cevallos
SMStephen D. McLeod
Stephen D. McLeod
TLThomas M. Lietman
Thomas M. Lietman
JRJennifer R. Rose-Nussbaumer
Jennifer R. Rose-Nussbaumer
Purpose: Understanding the spectrum of pathogens in a given geographic region is important when deciding on empiric antibiotic therapy. In this study, we evaluate the spectrum of bacterial organisms cultured from corneal samples and their antibiotic sensitivities to guide initial treatment of keratitis. Methods: We performed a retrospective case review of cultures from suspected infectious keratitis cases at the Francis I. Proctor Foundation, University of California, San Francisco, from 1996 through 2015. Logistic regression models were used to assess the risk of culturing methicillin-resistant Staphylococcus aureus (MRSA) from ulcers over time and the association between the year cultured and moxifloxacin resistance. Results: A total of 522 of 2203 (23.7%) cultures grew bacterial organisms believed to be the etiology of infection, with available antibiotic sensitivity data. Of these, 338 (65.3%) grew gram-positive organisms with the most common being methicillin-sensitive Staphylococcus aureus (20.1%, N = 105). One hundred eighty (34.7%) grew gram-negative species with Pseudomonas aeruginosa as the most prevalent organism (10.9%, N = 57). There was 1.13 increased odds of culturing MRSA for each 1-year increase in the culture date (P = 0.01) and 1.26 increased odds of culturing an organism resistant to moxifloxacin with each 1-year increase in the culture date after controlling for the infectious organism (P < 0.001). Conclusions: Gram-positive organisms are the most commonly identified etiology of microbial keratitis in this series. Approximately 35% of cultured organisms had variable susceptibility to moxifloxacin, and resistance seems to be increasing over time. The risk of culturing MRSA increased over time.

1 September 2017 in JAMA Ophthalmology
Verified
Journal Article
Closed access
NPN. Venkatesh Prajna
N. Venkatesh Prajna
TKTiruvengada Krishnan
Tiruvengada Krishnan
RRRevathi Rajaraman
Revathi Rajaraman
SPSushila Patel
Sushila Patel
RSRanjeet Shah
Ranjeet Shah
FGfor the Mycotic Ulcer Treatment Trial Group
for the Mycotic Ulcer Treatment Trial Group
Identifying patients with infectious keratitis who are at risk of experiencing a poor outcome may be useful to allocate resources toward high-risk patients, particularly in resource-poor settings. To determine baseline patient and ulcer characteristics that predict a high risk of developing corneal perforation and/or the need to undergo therapeutic penetrating keratoplasty (TPK). This is a secondary analysis of Mycotic Ulcer Treatment Trial II, a multicenter, double-masked, placebo-controlled randomized clinical trial that enrolled 240 patients with smear-positive filamentous fungal corneal ulcers who enrolled between May 2010 and August 2015. Participants had a baseline visual acuity of 20/400 or worse and were randomized to receive oral voriconazole or a placebo (all participants received topical voriconazole, 1%). After 39 participants (16.3%) were enrolled, topical natamycin, 5%, was also added. The primary outcome of this secondary analysis was the rate of corneal perforation or the need to undergo TPK. The mean (SD) age at enrollment was 49 (13) years, 104 participants (43.3%) were women, and all were of Southeast Asian descent. The presence of hypopyon at baseline indicated 2.28 times the odds of the patient developing corneal perforation and/or needing TPK (95% CI, 1.18-4.40; P = .01). Study participants whose infiltrate involved the posterior one-third had a 71.4% risk of developing corneal perforation and/or needing TPK. For each 1-mm increase in the geometric mean of the infiltrate, there was 1.37 (95% CI, 1.12-1.67; P = .002) increased odds of developing perforation and/or needing TPK. Other clinical features such as visual acuity, baseline culture positivity, type of filamentous fungal organism and duration of symptoms, and demographic characteristics, such as sex and occupation, were not significant predictors in the multivariable regression analysis. These results suggest that risk stratification from baseline ulcer characteristics can identify those at highest risk for developing corneal perforation and/or needing TPK. clinicaltrials.gov Identifier: NCT00996736.

1 February 2020 in Ophthalmology
Verified
Journal Article
Closed access
NPN. Venkatesh Prajna
N. Venkatesh Prajna
NRNaveen Radhakrishnan
Naveen Radhakrishnan
PLPrajna Lalitha
Prajna Lalitha
AAAriana Austin
Ariana Austin
KRKathryn J. Ray
Kathryn J. Ray
JRJennifer R. Rose-Nussbaumer
Jennifer R. Rose-Nussbaumer